Balcinrenone

A nonsteroidal antimineralocorticoid drug

Balcinrenone
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Balcinrenone is a nonsteroidal antimineralocorticoid that was developed for the treatment of congestive heart failure and hypertension. It acts as a selective mineralocorticoid receptor antagonist, blocking the effects of aldosterone in the body.

Mechanism of Action

Balcinrenone functions by inhibiting the action of aldosterone, a hormone that increases the reabsorption of sodium and water in the kidneys. By blocking aldosterone, balcinrenone promotes the excretion of sodium and water, which helps to lower blood pressure and reduce fluid overload in conditions such as congestive heart failure.

Pharmacokinetics

Balcinrenone is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily through the kidneys. The drug has a half-life that allows for once-daily dosing, making it convenient for patients.

Clinical Use

Balcinrenone was investigated for its potential use in treating conditions like heart failure and hypertension. However, it did not reach the market, and its development was discontinued. Despite this, the study of balcinrenone has contributed to the understanding of mineralocorticoid receptor antagonists and their role in cardiovascular therapy.

Side Effects

As with other mineralocorticoid receptor antagonists, potential side effects of balcinrenone may include hyperkalemia, hypotension, and renal impairment. Patients taking this class of drugs require monitoring of serum potassium levels and renal function.

Related Compounds

Balcinrenone is part of a class of drugs known as nonsteroidal antimineralocorticoids. Other drugs in this class include eplerenone and spironolactone, which are used clinically to treat similar conditions.

Research and Development

The development of balcinrenone was part of a broader effort to create more selective and effective mineralocorticoid receptor antagonists. Although balcinrenone itself was not marketed, research in this area continues to be important for developing new treatments for cardiovascular diseases.

Related pages

• Mineralocorticoid receptor antagonist
• Aldosterone
• Hypertension
• Heart failure